SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Thomas M. who wrote (1220)9/30/1998 9:16:00 PM
From: BMcV  Read Replies (1) | Respond to of 10280
 
Yes, there are generics on the market already, I believe.



To: Thomas M. who wrote (1220)10/1/1998 7:44:00 AM
From: Ed Ajootian  Respond to of 10280
 
Tom,

Bruce is right. Albuterol's patent expired several years ago.

Since there was no opportunity for the maker of Albuterol (Glaxo I believe) to extend its patent protection by getting levalbuterol, this made it less important for them to team up with SEPR to sell levalbuterol. This explains why SEPR is apparently going it alone on this one.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News